On February 17, 2017, upon the recommendation of the Nominating and Governance Committee of the board of directors of Neurotrope, Inc. (the “company”), the Board appointed Andrew D. Perlman as a member of the Board, effective immediately, to hold office until the next annual meeting of the stockholders of the company, until his successor is duly elected and qualified, or until his resignation or removal. Effective February 17, 2017, Mr. Perlman was appointed to serve as a member of the Audit Committee of the Board.